10.1038/onc.2017.38 Summary Keywords alcohol-associated liver disease (ALD), glucagon-like peptide 1 receptor agonists (GLP-1 RAs), metabolic dysfunction and alcohol-associated liver disease (MetALD), metabolic dysfunction-associated steatotic liver disease (MASLD), steatotic liver disease (SLD) Citation Mahalingam S, Kharbanda KK, Casey CA and Rasineni K (2026) Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum
Most menstrual irregularities associated with weight loss are temporary and resolve as the body adjusts to metabolic changes
Do I have to be overweight for GLP-1 to help my RA
As adoption and adherence grows, plan sponsors are keeping a close watch on clinical benefits and long-term financial impact
A balanced gut helps extract nutrients more efficiently from the smaller amount of food you are eating
Psoriasis is a skin disease that has symptoms including a rash and dry, scaly patches
